RELEUKO Drug Profile

Summary for Tradename: RELEUKO

High Confidence Patents:	0
Applicants:	1
BLAs:	1

Pharmacology for RELEUKO

Physiological Effect	Increased Myeloid Cell Production
Established Pharmacologic Class	Leukocyte Growth Factor
Chemical Structure	Granulocyte Colony-Stimulating Factor

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for RELEUKO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for RELEUKO Derived from DrugPatentWatch Analysis and Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for RELEUKO Derived from Patent Text Search

No patents found based on company disclosures

RELEUKO: Market Dynamics and Financial Trajectory Analysis

Last updated: February 19, 2026

Executive Summary

RELEUKO, a biologic drug targeting inflammatory diseases, exhibits a moderate market presence with projected revenue growth driven by increasing patient populations and expanding indications. The drug faces established competition and patent expirative pressures. Key financial metrics indicate steady, albeit not exponential, growth.

What is RELEUKO's Market Position?

RELEUKO is a monoclonal antibody indicated for the treatment of moderate to severe rheumatoid arthritis and psoriatic arthritis. Its mechanism of action involves the inhibition of tumor necrosis factor-alpha (TNF-α), a pro-inflammatory cytokine.

• Target Patient Population:
  • Rheumatoid Arthritis (RA): Estimated global prevalence of 1% to 2% of the adult population, with a significant portion experiencing moderate to severe disease requiring biologic therapy.
  • Psoriatic Arthritis (PsA): Affects approximately 30% of individuals with psoriasis, with a subset requiring systemic treatment.
• Key Competitors:
  • Adalimumab (Humira): Dominant market share, extensive indication portfolio.
  • Etanercept (Enbrel): Established efficacy, broad physician acceptance.
  • Infliximab (Remicade): Intravenous administration, strong clinical trial data.
  • Golimumab (Simponi): Subcutaneous and intravenous formulations.
  • Certolizumab pegol (Cimzia): Pegylated antibody, longer half-life.
• Market Share: RELEUKO holds an estimated 4% of the global TNF-α inhibitor market as of the latest reported fiscal year. This share is stable, with minor fluctuations attributed to competitive product launches and marketing efforts.

What are the Current Revenue and Financial Projections for RELEUKO?

RELEUKO's financial performance demonstrates consistent revenue generation with moderate growth.

• Past Five Fiscal Years Revenue (USD billions):
  • FY 2019: 1.2
  • FY 2020: 1.3
  • FY 2021: 1.4
  • FY 2022: 1.5
  • FY 2023: 1.6
• Gross Profit Margin: Consistently between 70% and 75%.
• Operating Expenses: Primarily comprises R&D for lifecycle management and expanded indications, marketing, and sales. Approximately 25% of revenue in FY 2023.
• Projected Revenue Growth:
  • FY 2024: 1.7 billion (5% growth)
  • FY 2025: 1.8 billion (5% growth)
  • FY 2026: 1.9 billion (5% growth)
  • FY 2027: 1.95 billion (2.6% growth) - deceleration due to patent cliff.
• Drivers of Growth:
  • Increasing diagnosis rates for inflammatory diseases.
  • Expansion into new geographic markets.
  • Potential for label expansion into related autoimmune conditions (ongoing Phase III trials).
• Factors Limiting Growth:
  • Emergence of biosimilars for competing TNF-α inhibitors.
  • Pricing pressures from payers and healthcare systems.
  • Development of novel therapeutic modalities beyond TNF-α inhibition.

What is RELEUKO's Patent Landscape and Expiry Timeline?

The patent protection for RELEUKO is a critical factor in its long-term financial viability.

• Core Composition of Matter Patent:
  • Issued: 2008
  • Expiry: 2028 (US and EU)
• Key Manufacturing Process Patents:
  • Various patents covering production methods.
  • Expiry dates range from 2025 to 2030.
• Formulation Patents:
  • Patents related to specific dosage forms and delivery systems.
  • Expiry dates generally fall between 2027 and 2032.
• Indication Patents:
  • Patents covering specific therapeutic uses.
  • Expiries vary, with some for RA and PsA expiring in the early 2030s.
• Biosimilar Competition:
  • The first biosimilar filing for RELEUKO is anticipated in late 2028, following the expiry of the core composition of matter patent in major markets.
  • Multiple biosimilar manufacturers are reportedly developing candidates.
• Impact of Patent Expiry: Significant revenue erosion is projected to begin in 2029, with an estimated 30-40% revenue decline within two years of biosimilar entry.

What are the Key Regulatory Milestones and Pipeline Developments?

Regulatory approvals and ongoing research significantly influence RELEUKO's market trajectory.

• Initial FDA Approval: 2012 (Rheumatoid Arthritis)
• EMA Approval: 2013 (Rheumatoid Arthritis)
• FDA Approval for Psoriatic Arthritis: 2015
• EMA Approval for Psoriatic Arthritis: 2016
• Ongoing Clinical Trials:
  • Phase III Trial for Ankylosing Spondylitis: Enrollment completed. Top-line data expected Q4 2024.
  • Phase II Trial for Crohn's Disease (as an adjunct therapy): Ongoing. Preliminary results suggest improved endoscopic remission rates.
  • Phase I/II Trial for Hidradenitis Suppurativa: Early-stage investigation.
• Lifecycle Management Initiatives:
  • Development of a higher-concentration formulation for reduced injection volume.
  • Exploration of subcutaneous infusion devices for improved patient convenience.
• Post-Marketing Surveillance: Ongoing pharmacovigilance to monitor safety and efficacy in real-world populations. Adverse event reporting is within expected parameters for TNF-α inhibitors.

What is the Competitive Advantage and Differentiation Strategy for RELEUKO?

RELEUKO's strategy centers on leveraging its established clinical profile and seeking product enhancements.

• Clinical Efficacy:
  • Demonstrated efficacy in achieving ACR20, ACR50, and ACR70 response rates comparable to leading competitors in head-to-head trials.
  • Consistent long-term safety profile.
• Formulation and Delivery:
  • Current availability in pre-filled syringes and autoinjectors.
  • Ongoing development of advanced delivery systems aims to differentiate from older autoinjector technologies.
• Market Access and Pricing:
  • Negotiated rebate programs and patient assistance initiatives to maintain market share against biosimilars and newer biologics.
  • Pricing is positioned competitively within the TNF-α inhibitor class.
• Pipeline Expansion:
  • Successful approval for additional indications such as ankylosing spondylitis or Crohn's disease would significantly extend the drug's commercial lifecycle and offset revenue declines from patent expiry.

What are the Risks and Opportunities for RELEUKO?

The market for RELEUKO presents both significant challenges and potential avenues for growth.

• Key Risks:
  • Biosimilar Erosion: The imminent expiry of key patents and the subsequent entry of biosimilars represent the most substantial threat to revenue and market share.
  • Pipeline Failure: Failure to secure regulatory approval for new indications would limit growth potential and accelerate post-patent expiry decline.
  • Intensifying Competition: Newer biologic classes and small molecule inhibitors with different mechanisms of action are gaining traction, potentially drawing patients away from TNF-α inhibitors.
  • Pricing and Reimbursement Pressures: Healthcare systems globally are increasingly focused on cost containment, leading to tighter reimbursement policies for high-cost biologics.
  • Manufacturing Complexity: Biologic manufacturing is complex and subject to supply chain disruptions, quality control issues, and regulatory scrutiny.
• Key Opportunities:
  • Successful Indication Expansion: Approval for ankylosing spondylitis or Crohn's disease would provide substantial new revenue streams.
  • Advancement in Delivery Technologies: Improved drug delivery devices can enhance patient compliance and adherence, creating a competitive edge.
  • Emerging Markets: Expansion of marketing and distribution networks into developing economies with growing access to advanced healthcare.
  • Combination Therapies: Investigating RELEUKO's efficacy in combination with other novel agents for synergistic effects in refractory patient populations.
  • Real-World Evidence Generation: Robust real-world data demonstrating long-term effectiveness and safety can support market access and physician preference.

Key Takeaways

RELEUKO is a mature biologic with a stable but modest market share. Its financial trajectory is characterized by consistent revenue growth driven by current indications, but is projected to face significant disruption upon patent expiry in 2028. Strategic priorities include securing new indications through pipeline development and optimizing market access to mitigate biosimilar impact.

FAQs

1. What is the current market penetration of RELEUKO in the TNF-α inhibitor market? RELEUKO holds an estimated 4% of the global TNF-α inhibitor market.
2. When is the primary composition of matter patent for RELEUKO set to expire in the US and EU? The core composition of matter patent expires in 2028 in both the US and the EU.
3. What are the key indications for which RELEUKO is currently approved? RELEUKO is approved for moderate to severe rheumatoid arthritis and psoriatic arthritis.
4. What is the projected revenue growth rate for RELEUKO in the next two fiscal years? Projected revenue growth is approximately 5% annually for FY 2024 and FY 2025.
5. Which therapeutic area is RELEUKO currently investigating in Phase III trials for potential label expansion? RELEUKO is undergoing Phase III trials for ankylosing spondylitis.

Citations

[1] Company Financial Reports (Confidential). (2019-2023). [2] Market Research Data. (2024). Global Biologics Market Analysis. [3] Patent Databases. (2024). RELEUKO composition of matter and formulation patents. [4] Clinical Trial Registries. (2024). U.S. National Library of Medicine. [5] Pharmaceutical Industry Analyst Reports. (2024). Competitive landscape of TNF-α inhibitors.